Karen Ignagni's big challenge is to turn around EmblemHealth's financial health

After almost a month in her new job as head of New York nonprofit insurer EmblemHealth, Karen Ignagni says she has shifted gears and is embracing the new challenges that come with actually running a health insurance plan.

In an interview with Crain's New York Business, Ignagni--who shocked Washington and the insurance industry when she announced in May she was leaving her job as head of America's Health Insurance Plans--talked about her new job with EmblemHealth, where she took over as president and CEO Sept. 1. It's a move that has taken her from being one of the country's most powerful lobbyists to leading the Manhattan-based insurer that has about 3.2 million members in New York state.

Ignagni said EmblemHealth's board has clearly decided that the company will remain a nonprofit insurer and will continue its mission of providing affordable coverage.

Her first challenge is turning around EmblemHealth's recent unprofitable status, since its subsidiaries Group Health Inc. and HIP Health Plan of New York, reported combined loses of $40 million in the first quarter, following a drop of $494 million in 2014 on $7 billion in revenue, Crain's reported. In sharp contrast, both were profitable from 2010 to 2013, with combined net income averaging $152 million, noted Crain's

Ignagni also said that since day one, she confronted issues facing the company with its employees.

She admits EmblemHealth's turnaround will include "right-sizing" the workforce and looking at restructuring its corporate management structure. She also expects to set up new contracts with hospitals with quality and performance standards, work with physicians on paying for value, and look at how to structure benefits, she told Crain's

To learn more:
- Read the interview

 

 

 

 

Suggested Articles

To reduce readmissions and create greater operational and cost efficiencies for providers and payers, we must rethink how we deliver and manage care.

Outpatient specialty drugs can be a lucrative income source for not-for-profit hospitals, but Washington presents some risks, Moody's says.

The growing role of data in our lives raises important questions about data access and ownership. Who rightfully owns the data?